IP Library Patent Application 15596529
Patent Application
App. No. 15/596,529

HYDROGEL COMPOSITIONS FOR USE IN CELL EXPANSION AND DIFFERENTIATION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/596,529
Abstract

Hydrogel compositions and methods of using hydrogel compositions are disclosed. Advantageously, the hydrogel compositions offer the ability to promote cellular expansion and/or cellular differentiation of various cells.

Claims (20)

1 . A hydrogel composition comprising an 8-arm, 20 kDa polyethylene glycol functionalized with norbornene, a crosslinking peptide, and a cell adhesion peptide.

2 . The hydrogel composition of claim 1 comprising at least 1 mM cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38).

3 . The hydrogel composition of claim 2 comprising a shear modulus range of from about 2 kPa to about 12 kPa.

4 . The hydrogel composition of claim 2 comprising a shear modulus of from about 1.8 kPa to about 33 kPa.

5 . The hydrogel composition of claim 1 comprising a concentration of polyethylene glycol of from about 36 mg/mL to about 160 mg/mL.

6 . The hydrogel composition of claim 1 comprising a concentration of polyethylene glycol of from about 36 mg/mL to about 70 mg/mL.

7 . The hydrogel composition of claim 1 comprising at least 0.25 mM of cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38).

8 . The hydrogel composition of claim 7 comprising a shear modulus of from about 3 kPa to about 16 kPa.

9 . The hydrogel composition of claim 1 further comprising an immobilized low molecular weight heparin.

10 . The hydrogel composition of claim 1 , wherein the crosslinking peptide is selected from the group consisting of KCGGPQGIWGQGCK (SEQ ID NO:27), KCGGPQGIAGQGCK (SEQ ID NO:28) and combinations thereof.

11 . The hydrogel composition of claim 1 comprising an extent of crosslinking, wherein the extent of crosslinking is from about 35% to about 75%.

12 . A hydrogel composition comprising a polyethylene glycol functionalized with norbornene, a crosslinking peptide, and at least 1 mM cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38), wherein the hydrogel composition comprises a shear modulus in the range of about 1.8 kPa to about 33 kPa.

13 . The hydrogel composition of claim 12 , wherein the shear modulus is in the range of about 2 kPa to about 12 kPa.

14 . The hydrogel composition of claim 12 comprising at least 0.25 mM of cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38).

15 . The hydrogel composition of claim 14 , wherein the shear modulus is in the range of from about 3 kPa to about 16 kPa.

16 . The hydrogel composition of claim 12 , wherein the crosslinking peptide is selected from the group consisting of KCGGPQGIWGQGCK (SEQ ID NO:27), KCGGPQGIAGQGCK (SEQ ID NO:28) and combinations thereof.

17 . A hydrogel composition comprising a polyethylene glycol functionalized with norbornene, a crosslinking peptide, and at least 1 mM cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38), wherein the hydrogel composition comprises a concentration of polyethylene glycol of from about 36 mg/mL to about 160 mg/mL.

18 . The hydrogel composition of claim 17 , wherein the concentration of polyethylene glycol is in the range of from about 36 mg/mL to about 70 mg/mL.

19 . The hydrogel composition of claim 17 comprising at least 0.25 mM of cell adhesion peptide selected from the group consisting of CRGDS (SEQ ID NO: 2), Acetylated-GCYGRGDSPG (SEQ ID NO:31), cyclic RGD (SEQ ID NO:35), CRGD-(G)13-PHSRN (SEQ ID NO:29), CPHSRN-(SG)5-RGD (SEQ ID NO:30) and IKVAV (SEQ ID NO:38).

20 . The hydrogel composition of claim 17 , wherein the crosslinking peptide is selected from the group consisting of KCGGPQGIWGQGCK (SEQ ID NO:27), KCGGPQGIAGQGCK (SEQ ID NO:28) and combinations thereof.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 25, 2018
From: UNIVERSITY OF WISCONSIN-MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046245/0820 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2017
From: MURPHY, WILLIAM; PARLATO, MATTHEW; LE, NGOC NHI; MOLENDA, JAMES
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 042394/0736 →